OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive astrocytoma WHO grade IV.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Rozpoznanie nawrotowego lub postępującego glejaka mózgu (WHO Grade IV) lub astrocytoma (WHO Grade IV)
- •Potwierdzenie wzrostu nowotworu badaniem MRI mózgu
- •Badanie MRI wykonane w ciągu 28 dni przed włączeniem do badania
- •Co najmniej 12 tygodni od końca radioterapii (z wyjątkami przy potwierdzonym nawrocie)
- •Ogólny stan zdrowia pozwalający na leczenie (skala Karnofsky'ego ≥60%)
- •Nowotwór nadający się do laserowej ablacji i urządzenia Optune GIO®
- •Prawidłowe wyniki badań krwi i funkcji organów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UF Health Shands Hospital
Gainesville, United States
Trial contact
Victoria Hope
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.